DA Davidson Weighs in on Core Laboratories NV’s Q3 2016 Earnings (CLB)
Core Laboratories NV (NYSE:CLB) – Equities researchers at DA Davidson issued their Q3 2016 earnings per share (EPS) estimates for shares of Core Laboratories NV in a report released on Wednesday. DA Davidson analyst S. Randhawa expects that the brokerage will post earnings per share of $0.39 for the quarter. DA Davidson has a “Buy” rating and a $136.00 price target on the stock. DA Davidson also issued estimates for Core Laboratories NV’s Q4 2016 earnings at $0.43 EPS, FY2016 earnings at $1.54 EPS, Q1 2017 earnings at $0.50 EPS, Q2 2017 earnings at $0.54 EPS, Q3 2017 earnings at $0.66 EPS, Q4 2017 earnings at $0.76 EPS and FY2017 earnings at $2.46 EPS.
Several other research analysts also recently commented on CLB. Citigroup Inc. lowered their target price on Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating for the company in a research note on Monday, July 25th. KLR Group reissued a “buy” rating and set a $180.00 target price (up previously from $166.00) on shares of Core Laboratories NV in a research note on Monday, June 13th. Zacks Investment Research downgraded Core Laboratories NV from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Credit Suisse Group AG started coverage on Core Laboratories NV in a research note on Thursday, September 1st. They set a “neutral” rating and a $115.00 target price for the company. Finally, Loop Capital assumed coverage on Core Laboratories NV in a research note on Friday, September 30th. They issued a “hold” rating and a $120.00 price objective for the company. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. Core Laboratories NV presently has a consensus rating of “Hold” and an average target price of $121.33.
Shares of Core Laboratories NV (NYSE:CLB) opened at 113.34 on Monday. The firm has a market capitalization of $5.00 billion, a P/E ratio of 60.13 and a beta of 1.45. The firm’s 50-day moving average is $111.18 and its 200 day moving average is $117.50. Core Laboratories NV has a one year low of $84.50 and a one year high of $135.49.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/da-davidson-weighs-in-on-core-laboratories-nvs-q3-2016-earnings-clb.html
Core Laboratories NV (NYSE:CLB) last announced its earnings results on Wednesday, July 20th. The company reported $0.35 EPS for the quarter, hitting the consensus estimate of $0.35. The firm had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The business’s quarterly revenue was down 27.4% on a year-over-year basis. During the same period last year, the company posted $0.81 EPS.
Several institutional investors have recently bought and sold shares of CLB. Balentine LLC boosted its position in Core Laboratories NV by 44.3% in the second quarter. Balentine LLC now owns 893 shares of the company’s stock worth $111,000 after buying an additional 274 shares during the last quarter. MU Investments Co. Ltd. purchased a new position in shares of Core Laboratories NV during the second quarter worth $115,000. Advisory Services Network LLC raised its position in shares of Core Laboratories NV by 33.2% in the third quarter. Advisory Services Network LLC now owns 1,062 shares of the company’s stock worth $119,000 after buying an additional 265 shares during the last quarter. Pinkerton Retirement Specialists LLC purchased a new position in shares of Core Laboratories NV during the second quarter worth $127,000. Finally, Fifth Third Bancorp raised its position in shares of Core Laboratories NV by 15.3% in the second quarter. Fifth Third Bancorp now owns 1,166 shares of the company’s stock worth $144,000 after buying an additional 155 shares during the last quarter.
Core Laboratories NV Company Profile
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Receive News & Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related companies with MarketBeat.com's FREE daily email newsletter.